Answers are grounded in this paper and cite their sources.
Retrospective analysis evaluates the prognostic role of SUVmax on SBRT outcomes in early-stage NSCLC, indicating treatment timing influences efficacy based on metabolic activity.
Objective To investigate the prognostic value of pretreatment SUVmax in early-stage NSCLC treated with stereotactic body radiotherapy (SBRT) and evaluate whether metabolic activity modulates the impact of overall treatment time (OTT) on outcomes. Methods We retrospectively analyzed 186 patients with stage I NSCLC treated with SBRT (48 Gy/4 fractions). Patients were stratified into high (SUVmax ≥5.0, n=73) and low (SUVmax <5.0, n=113) metabolic groups. Schedules were categorized as consecutive (OTT 4–5 days) or non-consecutive (OTT 6–10 days). Primary endpoints were local control (LC) and overall survival (OS). Results With a median follow-up of 41 months, high SUVmax was associated with inferior outcomes; the 3-year LC rates were 92.1% in the low metabolic group compared to 63.4% in the high metabolic group (p<0.0001). On multivariate analysis, SUVmax ≥5.0 independently predicted local failure (HR 3.70, 95% CI 1.48–9.24, P = 0.005) and mortality (HR 2.38, 95% CI 1.41–4.01, P = 0.001). Crucially, a formal interaction test revealed that metabolic activity significantly modulated the impact of scheduling on LC (P-interaction = 0.042). Subgroup analysis demonstrated that consecutive treatment significantly improved LC in the high-SUVmax group (P = 0.035), whereas no significant difference between schedules was observed in the low-SUVmax group (P = 0.57). Conclusion Pretreatment SUVmax is a robust prognostic biomarker for SBRT outcomes. High-metabolic tumors exhibit heightened sensitivity to treatment prolongation, likely driven by factors such as accelerated repopulation during gaps. Consequently, relatively short or consecutive SBRT courses may be beneficial for this "high-risk" metabolic subgroup. However, biological prioritization must be balanced against safety; non-consecutive schedules remain viable for indolent tumors and are mandatory when technical limitations, prior radiotherapy, or central/ultra-central tumor locations preclude the safe delivery of highly compressed ablative doses. Micro-Abstract This study reveals that the benefit of consecutive daily SBRT for early-stage NSCLC depends on tumor metabolic activity. Patients with high pretreatment SUVmax (≥5.0) achieved significantly better local control with consecutive treatment, whereas treatment gaps did not compromise outcomes in low-metabolic tumors. While relatively short SBRT courses may benefit high-SUVmax tumors by mitigating accelerated repopulation, protracted schedules remain a mandatory safety measure when technical limitations, central locations, or prior radiotherapy preclude the safe delivery of compressed doses.
No takes yet. Share an insight, caveat, or question.
Di et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: